Japan Tissue Engineering Co., Ltd. (7774.T)

JPY 457.0

(-2.35%)

Market Cap (In JPY)

18.55 Billion

Revenue (In JPY)

2.51 Billion

Net Income (In JPY)

143.16 Million

Avg. Volume

58.47 Thousand

Currency
JPY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
455.0-811.0
PE
-
EPS
-
Beta Value
0.403
ISIN
JP3389610001
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Ken-Ichiro Hata D.D.S., Ph.D.
Employee Count
-
Website
https://www.jpte.co.jp
Ipo Date
2007-12-28
Details
Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it researches and develops human 3-dimensional cultured tissue models for use in the development of cosmetics and drugs for external use, as well as in research that employs skin and cornea tissues. Further, the company offers regenerative medicine contract development and manufacturing services. The company was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. is a subsidiary of Teijin Limited.